Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of RO7020531 in Healthy Volunteers and Chronic Hepatitis B Patients
NCT02956850Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2016
- Primary completion
- Jun 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial of ruzotolimod in Chronic Hepatitis B (CHB) (3 arms), sponsored by Roche. Primary endpoints: Percentage of SAD Participants With Adverse Events at Day 29, Percentage of MAD Participants With Adverse Events at Day 41 and 10 more. Started Dec 2016; status: completed.
02
Drugs
ruzotolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02956850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956850.